April #100 : Warning Signs

POZ - Health, Life and HIV
Subscribe to:
POZ magazine
E-newsletters
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join
Username:
Password:

Back to home » Archives » POZ Magazine issues




Table of Contents

Getting Out Alive

Last Call

He Said, He Said

Outside In

Myth vs. Reality in the Pen

The Hook-Up

Africa’s Mayor

3 x 5 Report Card

Tribute: Wilfredo Valencia Palacios Roman

Earthwatch: Prison Focus

Website of the month: AIDSVote.org

Medicare Malaise

See You in the Lobby

Show & Tell: Oscar Time

Milestones

TeleVisionaries

Cirque du So Lame

Can HIV Care Click in the Clink?

A Bitter Pill

Comfort Zone: SpiceBoy

The Sweetest Taboo

Diamond in the Roughage

Head Games

Looking for Liver Helpers

Quick Study: Painkiller

Briefs

Cheek to Chic

Warning Signs

Quick Study: Sexual Satisfaction

Publisher’s Letter

Mailbox

Live To Tell: With Conviction



Most Popular Lessons

The HIV Life Cycle

Shingles

Herpes Simplex Virus

Syphilis & Neurosyphilis

Treatments for Opportunistic Infections (OIs)

What is AIDS & HIV?

Hepatitis & HIV


email print

April 2004

Warning Signs

Viramune: Boehringer Ingelheim (BI), maker of the non-nuke Viramune (nevirapine), is issui

Viramune: Boehringer Ingelheim (BI), maker of the non-nuke Viramune (nevirapine), is issuing a “Dear Doctor” letter saying the med may spell trouble in first-line combos for women with CD4 counts over 250 and men over 400.

Viramune boosts those women’s risk of liver disease and rash almost tenfold (from 1.1 percent to 9.7 percent), the men’s almost seven times (from 0.7 percent to 3.6 percent). HIV expert Antonio Urbina, MD, says high CD4 counts invite danger because stronger immune systems are more likely to attack Viramune as an invader. But he says, “The warning applies only to those about to start Viramune. For those on it and doing well, there’s no need to stop or switch meds.”

“Viramune already had a black-box warning [for] fatal liver toxicity, including hepatitis and necrosis, in patients with high CD4 counts,” says an FDA spokesperson, adding that you should watch for the problems for 18 weeks, though the greatest risk falls in the first six weeks of treatment.




[Go to top]

Join POZ Facebook Twitter Google+ MySpace YouTube Tumblr Flickr
Quick Links
Current Issue

HIV 101
HIV Testing
Safer Sex
Find a Date
Newly Diagnosed
Disclosing Your Status
Starting Treatment
Search for the Cure
POZ Stories
POZ TV
Read the Blogs
Visit the Forums
Women
African American
Latino
Providers
Job Listings
Events Calendar


    chrisf
    san jose
    California


    mtaj0818
    Washington
    DC


    TaintedloveDC
    Washington
    DC


    robert12
    Queens
    New York
Click here to join POZ Personals!
Ask POZ Pharmacist

Talk to Us
Poll
Do you enjoy books with HIV-positive characters?
Yes
No

Survey
Mind Matters

more surveys
Contact Us
We welcome your comments!
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertising policy | advertise/contact us | site map]
© 2014 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.